The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor

Chest

Volumn 141, Issue 2, 2012, Pages 477-484

  Hollevoet, Kevin ^a   Nackaerts, Kristiaan ^c   Thas, Olivier ^b   Thimpont, Joël ^e   Germonpré, Paul ^d   De Vuyst, Paul ^e   Bosquée, Lionel ^f   Legrand, Catherine ^g   Kellen, Eliane ^c   Kishi, Yoshiro ^h   Delanghe, Joris R ^a   Van Meerbeeck, Jan P ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^e ERASME HOSPITAL   (Belgium)

^f UNIVERSITY OF LIÈGE   (Belgium)

^g UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^h Medical & Biological Laboratories Co Ltd   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GROWTH FACTOR; MEGAKARYOCYTE POTENTIATING FACTOR; MESOTHELIN; PEMETREXED; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CANCER STAGING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MESOTHELIOMA; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SURVIVAL;

EID: 84856711970     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-0129     Document Type: Article

References (29)

1. van Meerbeeck JP, Scherpereel A, Surmont VF, et al. Malignant pleural mesothelioma:the standard of care and challenges for future management. Crit Rev Oncol Hematol. 2011;78(2):92-111. doi:
2. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer. 2008;44(1):46-53. (Pubitemid 350262830)
3. Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 2003;362(9396):1612-1616. (Pubitemid 37443528)
4. Hollevoet K, Nackaerts K, Thimpont J, et al. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. Am J Respir Crit Care Med. 2010;181(6):620-625.
5. Hassan R, Remaley AT, Sampson ML, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res. 2006;12(2):447-453. (Pubitemid 43166134)
6. Hollevoet K, Bernard D, De Geeter F, et al. Glomerular filtration rate is a confounder for the measurement of soluble mesothelin in serum. Clin Chem. 2009;55(7):1431-1433.
7. Weber DG, Johnen G, Taeger D, et al. Assessment of confounding factors affecting the tumor markers SMRP, CA125, and CYFRA21-1 in serum. Biomark Insights. 2010;5:1-8.
8. Lowe KA, Shah C, Wallace E, et al. Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(9):2480-2487.
9. Park EK, Thomas PS, Creaney J, Johnson AR, Robinson BW, Yates DH. Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population. Clin Chem Lab Med. 2010;48(6):869-874.
10. Cristaudo A, Foddis R, Vivaldi A, et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res. 2007;13(17):5076-5081. (Pubitemid 47502073)
11. Grigoriu BD, Scherpereel A, Devos P, et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res. 2007;13(10):2928-2935. (Pubitemid 46850705)
12. Schneider J, Hoffmann H, Dienemann H, Herth FJ, Meister M, Muley T. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. J Thorac Oncol. 2008;3(11):1317-1324.
13. Pass HI, Wali A, Tang N, et al. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg. 2008;85(1):265-272. (Pubitemid 350265805)
14. Creaney J, Yeoman D, Naumoff LK, et al. Soluble mesothelin in effusions:a useful tool for the diagnosis of malignant mesothelioma. Thorax. 2007;62(7):569-576. (Pubitemid 47056881)
15. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer. 1996;14(1):1-12.
16. Levey AS, Stevens LA, Schmid CH, et al CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612.
17. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease:evaluation, classifica tion, and stratification. Am J Kidney Dis. 2002;39(2 suppl 1):S1-S266.
18. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-655. (Pubitemid 13149996)
19. Beyer HL, Geschwindt RD, Glover CL, et al. MESOMARK: a potential test for malignant pleural mesothelioma. Clin Chem. 2007;53(4):666-672. (Pubitemid 46580236)
20. Iwahori K, Osaki T, Serada S, et al. Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin. Lung Cancer. 2008;62(1):45-54.
21. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148(3):839-843. (Pubitemid 13033817)
22. Mandrekar JN, Mandrekar SJ, Cha SS. Cutpoint Determination Methods in Survival Analysis Using SAS. Seattle, WA: SAS Users Group International Proceedings;2003:261-282.
23. Baillargeon J, Pollock BH, Kristal AR, et al. The association of body mass index and prostate-specific antigen in a population- based study. Cancer. 2005;103(5):1092-1095. (Pubitemid 40270087)
24. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA. 1993;270(7):860-864. (Pubitemid 23234116)
25. Sturgeon CM, Duffy MJ, Stenman UH, et al National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008;54(12):e11- e79.
26. Greene KL, Albertsen PC, Babaian RJ, et al. Prostate specific antigen best practice statement:2009 update. J Urol. 2009;182(5):2232-2241.
27. Harris EK, Boyd JC. On dividing reference data into subgroups to produce separate reference ranges. Clin Chem. 1990;36(2):265-270.
28. Cristaudo A, Foddis R, Bonotti A, et al. Polymorphisms in the putative micro-RNA-binding sites of mesothelin gene are associated with serum levels of mesothelin-related protein. Occup Environ Med. 2010;67(4):233-236.
29. Nelson HH, Almquist LM, LaRocca JL, et al. The relationship between tumor MSLN methylation and serum mesothelin (SMRP) in mesothelioma. Epigenetics. 2011;6(8):1029-1034.